Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disposition of [¹⁴C]Prexasertib in Advanced Solid Tumors
NCT02778126Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prexasertib in solid tumor (advanced stage), sponsored by Eli Lilly and Company. Primary endpoints: Urinary Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered, Fecal Excretion of LY2606368 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered and 1 more. Started Sep 2016; status: completed.
02
Drugs
prexasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02778126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02778126.